Yoonyoung Choi

Yoonyoung Choi

Auto-generated profile, based on publicly available information

Yoonyoung Choi

Epidemiology, Merck & Co., Inc., Rahway, NJ 07065, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2021 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PDF file
YCYoonyoung Choi
Yoonyoung Choi
AHAlexandra Hill‐Ricciuti
Alexandra Hill‐Ricciuti
ABAngela R. Branche
Angela R. Branche
WSWilliam D. Sieling
William D. Sieling
LSLisa Saiman
Lisa Saiman
LFLyn Finelli
Lyn Finelli
Background: Respiratory syncytial virus (RSV) infections are common in adults, but data describing the cost of RSV‐associated hospitalization are lacking due to inconsistency in diagnostic coding and incomplete case ascertainment. We evaluated costs of RSV‐associated hospitalization in adult patients with laboratory‐confirmed, community‐onset RSV.Methods: We included adults ≥ 18 years of age admitted to three hospital systems in New York during two RSV seasons who were RSV‐positive by polymerase chain reaction (PCR) and had more than or equal to two acute respiratory infection symptoms or exacerbation of underlying cardiopulmonary disease. We abstracted costs from hospital finance systems or converted hospital charges to cost using cost‐charge ratios. We converted cost into 2020 US dollars and extrapolated to the United States. We used a generalized linear model to determine predictors of hospitalization cost, stratified by admission to intensive care units (ICU).Results: Cost data were available for 79% (601/756) of eligible patients. The mean total cost of hospitalization was $8403 (CI95 $7240–$9741). The highest costs were those attributed to ICU services $7885 (CI95 $5877–$10,240), whereas the lowest were radiology $324 (CI95 $275–$376). Other than longer length of stay, predictors of higher cost included having chronic liver disease (odds ratio [OR] 1.38 [CI95 1.05–1.80]) for patients without ICU admission and antibiotic use (OR 1.49 [CI95 1.10–2.03]) for patients with ICU admission. The annual US cost was estimated to be $1.2 (CI95 0.9–1.4) billion.Conclusion: The economic burden of RSV hospitalization of adults ≥ 18 years of age in the United States is substantial. RSV vaccine programs may be useful in reducing this economic burden.

1 December 2016 in Papillomavirus Research
Verified
Journal Article
Open access
YCYoonyoung Choi
Yoonyoung Choi
EEEfe Eworuke
Efe Eworuke
RSRichard Segal
Richard Segal
To identify factors that explain differences in HPV vaccination rates for male and female adolescents and to determine self-reported barriers by parents affecting vaccination decisions. The sample included adolescents 13-17 years old with a vaccination record documented in the 2012 and 2013 National Immunization Survey-Teen dataset. A logistic regression model was developed with 13 socio-demographic factors and survey year, along with significant interaction pairs with gender. Subjects included 20,355 and 18,350 adolescent boys and girls, respectively. About half of the females (56%) received at least one dose of HPV vaccine, compared to 28% of males. Several factors differed between males and females, including higher vaccination rates among non-Hispanic Black males and lower vaccination rates for non-Hispanic Black females compared to Whites; and a stronger association with health care provider recommendation among males. The most common parental reasons for not vaccinating their children included 'not recommended by a health care provider' for males (24%), and 'unnecessary' for females (18%). We found a significant gender interaction with several socio-demographic variables in predicting vaccination uptake. These gender differences may be partially an artifact of timing, because male vaccination became routine approximately five years after female vaccination.

4 September 2020 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Open access
MPMatthew Phillips
Matthew Phillips
LFLyn Finelli
Lyn Finelli
LSLisa Saiman
Lisa Saiman
CWChengbin Wang
Chengbin Wang
YCYoonyoung Choi
Yoonyoung Choi
JPJanak Patel Patel
Janak Patel Patel
Despite recent declines in the incidence of acute otitis media (AOM), more than 5 million cases and 5–6 million primary AOM visits still occur in young children in the United States, resulting in $4.4 billion direct medical costs annually. Our aims in this review are to describe the role of respiratory syncytial virus (RSV) in the etiology of AOM, discuss the prospect of prevention of RSV-associated AOM through immunization, and suggest future research strategies to assess the impact of immunization on RSV-associated AOM.

1 July 2024 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PTPhuong T. Tran
Phuong T. Tran
SNSabina O. Nduaguba
Sabina O. Nduaguba
YWYanning Wang
Yanning Wang
VDVakaramoko Diaby
Vakaramoko Diaby
LFLynn Finelli
Lynn Finelli
AWAlmut G. Winterstein
Almut G. Winterstein
Background: The cost of medically attended RSV LRI (lower respiratory infection) is critical in determining the economic value of new RSV immunoprophylaxes. However, most studies have focused on intermittent RSV encounters, not the episode of care that captures the entirety of RSV illness.Methods: We created age‐ and condition‐specific cohorts of children under 5 years of age using MarketScan® data (2015–2019). We contrasted aggregating healthcare costs over RSV‐LRTI episodes to ascertaining costs based on RSV‐specific encounters only. Economic burden was estimated by multiplying costs per encounter or per episode by their respective incidence rates.Results: Average cost was higher per episode than per encounter regardless of settings (inpatient: $28,586 vs. $18,056 and outpatient/ED: $2099 vs. $407 for infants). Across ages, the economic burden was highest for infants and RSV‐LRTI requiring inpatient care, but the burden in outpatient/ED settings was disproportionately higher than costs due to higher incidence rates (for inpatient vs. outpatient episodes: $226,403 vs. $101,269; for inpatient vs. outpatient encounters: $151,878 vs. $38,819 per 1000 infant‐years). For high‐risk children, cost and burden were up to 3–10 times higher, respectively.Conclusions: With a comprehensive stratification by settings and risk condition, the encounter‐ versus episode‐based estimates provide a robust range for policymakers' economic appraisal of new RSV immunoprophylaxes.

20 April 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
ABAna Luiza Bierrenbach
Ana Luiza Bierrenbach
YCYoonyoung Choi
Yoonyoung Choi
PBPaula Batista
Paula Batista
FSFernando Brandão Serra
Fernando Brandão Serra
CPCintia Irene Parellada
Cintia Irene Parellada
TMThais Moreira
Thais Moreira
Background: In 2014, a recommended one-dose of inactivated hepatitis A vaccine was included in the Brazilian National Immunization Program targeting children 12–24 months. This decision addressed the low to intermediate endemicity status of hepatitis A across Brazil and the high rate of infection in children and adolescents between 5 and 19 years old. The aim of the study was to conduct a time-series analysis on hepatitis A incidence across age groups and to assess the hepatitis A distribution throughout Brazilian geographic regions. Methods: An interrupted time-series analysis was performed to assess hepatitis A incidence rates before (2010–2013) and after (2015–2018) hepatitis A vaccine program implementation. The time-series analysis was stratified by age groups while a secondary analysis examined geographic distribution of hepatitis A cases. Results: Overall incidence of hepatitis A decreased from 3.19/100.000 in the pre-vaccine period to 0.87/100.000 (p = 0.022) post-vaccine introduction. Incidence rate reduction was higher among children aged 1-4 years old, with an annual reduction of 67.6% in the post-vaccination period against a 7.7% annual reduction in the pre-vaccination period (p < 0.001). Between 2015 and 2018, the vaccination program prevented 14,468 hepatitis A cases. Conclusion: Our study highlighted the positive impact of a recommended one-dose inactivated hepatitis A vaccine for 1–4-years-old in controlling hepatitis A at national level.

18 October 2023 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Open access
PDF file
YCYoonyoung Choi
Yoonyoung Choi
LFLynn Finelli
Lynn Finelli
We evaluated costs for respiratory syncytial virus (RSV) medical attention in children aged <24 months using MarketScan® Medicaid Multi-State claims database 2015–2019. Average cost was highest for RSV hospitalization with intensive care unit (ICU) admission ($23 514–24 835), followed by no ICU admission ($8039–8990), ED visits ($463–482), and outpatient visits ($145–151). Cost was higher for those with comorbidities.